{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:58:27Z","timestamp":1715993907258},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,1,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Limited efficacy and safety data exist from open-label clinical trials of phosphodiesterase 5 inhibitors in men with erectile dysfunction (ED) and multiple comorbid (MCM) conditions, historically a difficult group to treat.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>A multicenter study (Multiple Observations in Men with Erectile Dysfunction in National Tadalafil Study in the US) assessed efficacy and safety of tadalafil in men with ED and MCM conditions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures<\/jats:title>\n                  <jats:p>The primary end point was change from baseline in the erectile function (EF) domain of the International Index of Erectile Function. Secondary end points included the Sexual Encounter Profile, Global Assessment Questions, and Sexual Self-Confidence and Spontaneity Domains of the Psychological and Interpersonal Relationship Scales.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was an open-label, multicenter study in men with ED. Tadalafil 20 mg was administered as needed prior to sexual activity, up to once\/day, for 12 weeks following a 4-week ED-treatment-free period. The MCM group was 155 of 1,911 men enrolled in this study. Men in the MCM group met eligibility criteria but could not be included in other predefined groups: (i) Caucasian; (ii) Black American; (iii) Hispanic (groups 1\u20133, \u226465 years, no diabetes or depression); (iv) depression, \u226465 years, no diabetes; (v) diabetes, \u226465 years, no depression; (vi) &amp;gt;65 years, no diabetes or depression; and (vii) ED subsequent to traumatic spinal cord injury.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Mean baseline EF domain score in MCM (mean age 65 \u00b1 9 years) was 12.2 \u00b1 6.5; 52% of subjects had severe ED; 72% diabetes mellitus; 67% cardiovascular disease (including hypertension); 49% hyperlipidemia; 38% depression; 84% had two or more comorbidities. At end point, there was a significant (P &amp;lt;0.001) mean change of 7.6 from baseline in mean EF domain score. Among men with severe ED, 22% achieved an EF domain score \u226526. Most common adverse events were headache 5.2%; flushing 3.9% and nasal congestion 3.2%; 3% discontinued use because of an adverse event.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In this open-label clinical trial of older men with ED and MCMs, tadalafil 20 mg significantly increased all efficacy end points and was well-tolerated.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/j.1743-6109.2006.00402.x","type":"journal-article","created":{"date-parts":[[2007,1,4]],"date-time":"2007-01-04T06:17:30Z","timestamp":1167891450000},"page":"166-175","source":"Crossref","is-referenced-by-count":38,"title":["Efficacy and Safety of Tadalafil in Men with Erectile Dysfunction with a High Prevalence of Comorbid Conditions: Results from MOMENTUS: Multiple Observations in Men with Erectile Dysfunction in National Tadalafil Study in the US"],"prefix":"10.1093","volume":"4","author":[{"given":"Irwin","family":"Goldstein","sequence":"first","affiliation":[{"name":", Milton, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Kim","sequence":"additional","affiliation":[{"name":"University of Tennessee , Knoxville , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William D.","family":"Steers","sequence":"additional","affiliation":[{"name":"University of Virginia , Charlottesville , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon L.","family":"Pryor","sequence":"additional","affiliation":[{"name":"University of Minnesota , Minneapolis , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dixon W.","family":"Wilde","sequence":"additional","affiliation":[{"name":"ICOS Corporation , Bothell , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanni","family":"Natanegara","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Eli Lilly and Company , Indianapolis , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Wong","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Eli Lilly and Company , Indianapolis , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjeev","family":"Ahuja","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Eli Lilly and Company , Indianapolis , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2007,1,1]]},"reference":[{"key":"2024032600410628500_bib1","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.ijir.3900622","article-title":"Epidemiology of erectile dysfunction: Results of the \u201cCologne Male Survey.\u201d","volume":"12","author":"Braun","year":"2000","journal-title":"Int J Impot Res"},{"key":"2024032600410628500_bib2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1161\/01.CIR.0000133278.81226.C9","article-title":"Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients","volume":"110","author":"Gazzaruso","year":"2004","journal-title":"Circulation"},{"key":"2024032600410628500_bib3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jacc.2003.07.042","article-title":"Impaired brachial artery endothelium-dependent and\u2014Independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease","volume":"43","author":"Kaiser","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2024032600410628500_bib4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2003.11.002","article-title":"Erectile dysfunction: The earliest sign of generalized vascular disease?","volume":"43","author":"Cheitlin","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2024032600410628500_bib5","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.eururo.2005.05.014","article-title":"Is erectile dysfunction an indicator for increased risk of coronary heart disease and stroke?","volume":"48","author":"Ponholzer","year":"2005","journal-title":"Eur Urol"},{"key":"2024032600410628500_bib6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-5347(17)34871-1","article-title":"Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study","volume":"151","author":"Feldman","year":"1994","journal-title":"J Urol"},{"key":"2024032600410628500_bib7","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1046\/j.1464-410X.2003.04093.x","article-title":"Phamacological management of erectile dysfunction","volume":"91","author":"Montorsi","year":"2002","journal-title":"BJU Int"},{"key":"2024032600410628500_bib8","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/S0022-5347(05)64442-4","article-title":"Efficacy and safety of tadalafil for the treatment of erectile dysfunction: Results of integrated analyses","volume":"168","author":"Brock","year":"2002","journal-title":"J Urol"},{"key":"2024032600410628500_bib9","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1464-410X.2004.04819.x","article-title":"The efficacy and safety of tadalafil: An update","volume":"93","author":"Carson","year":"2004","journal-title":"BJU Int"},{"key":"2024032600410628500_bib10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1743-6109.2004.04024.x","article-title":"Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events","volume":"1","author":"Jackson","year":"2004","journal-title":"J Sex Med"},{"key":"2024032600410628500_bib11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1743-6109.2005.00068.x","article-title":"The efficacy of tadalafil in clinical populations","volume":"2","author":"Lewis","year":"2005","journal-title":"J Sex Med"},{"key":"2024032600410628500_bib12","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1743-6109.2006.00209.x","article-title":"Efficacy and safety of tadalafil across ethnic groups and various risk factors in men with erectile dysfunction: Use of a novel noninferiority study design","volume":"3","author":"Morgentaler","year":"2006","journal-title":"J Sex Med"},{"key":"2024032600410628500_bib13","article-title":"Tadalafil is efficacious in Black American and Hispanic men with Erectile Dysfunction (ED): Results from Multiple Observations in Men With ED in National Tadalafil Study in the US (MOMENTUS)","author":"Gomery","year":"2006,  18","journal-title":"Int J Impot Res"},{"key":"2024032600410628500_bib14","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0090-4295(97)00238-0","article-title":"The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction","volume":"49","author":"Rosen","year":"1997","journal-title":"Urology"},{"key":"2024032600410628500_bib15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1023\/B:ASEB.0000007459.48511.31","article-title":"The Psychological and Interpersonal Relationship Scales: Assessing psychological and relational outcomes associated with erectile dysfunction and its treatment","volume":"33","author":"Swindle","year":"2004","journal-title":"Arch Sex Behav"},{"key":"2024032600410628500_bib16","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJM199805143382001","article-title":"Oral sildenafil in the treatment of erectile dysfunction","volume":"338","author":"Goldstein","year":"1998","journal-title":"N Engl J Med"},{"key":"2024032600410628500_bib17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1046\/j.1464-410x.2001.00998.x","article-title":"A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction","volume":"87","author":"Meuleman","year":"2001","journal-title":"BJU Int"},{"key":"2024032600410628500_bib18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0090-4295(03)00115-8","article-title":"Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: Results of a randomized, double-blind, 26-week placebo-controlled pivotal trial","volume":"61","author":"Hellstrom","year":"2003","journal-title":"Urology"},{"key":"2024032600410628500_bib19","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.eururo.2004.01.014","article-title":"The efficacy and safety of flexible-dose vardenafil (Levitra (registered trademark)) in a broad population of European men","volume":"45","author":"Hatzichristou","year":"2004","journal-title":"Eur Urol"},{"key":"2024032600410628500_bib20","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2337\/diacare.25.12.2159","article-title":"Effects of tadalafil on erectile dysfunction in men with diabetes","volume":"25","author":"Saenz de Tejada","year":"2002","journal-title":"Diabetes Care"},{"key":"2024032600410628500_bib21","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.281.5.421","article-title":"Sildenafil for treatment of erectile dysfunction in men with diabetes: A randomized controlled trial","volume":"281","author":"Rendell","year":"1999","journal-title":"J Am Med Assoc"},{"key":"2024032600410628500_bib22","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2337\/diacare.26.3.777","article-title":"Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: A multicenter double-blind placebo-controlled fixed-dose study","volume":"26","author":"Goldstein","year":"2003","journal-title":"Diabetes Care"},{"key":"2024032600410628500_bib23","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1097\/01.ju.0000125198.32936.38","article-title":"The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction","volume":"171","author":"Seftel","year":"2004","journal-title":"J Urol"},{"key":"2024032600410628500_bib24","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1743-6109.2005.00102.x","article-title":"Sexual intercourse attempt patterns with two dosing regimens of tadalafil in men with erectile dysfunction: Results from the SURE study in 14 European countries","volume":"2","author":"Moncada","year":"2005","journal-title":"J Sex Med"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S174360951531482X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S174360951531482X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/4\/1\/166\/47808753\/jsm_4_1_166.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/4\/1\/166\/47808753\/jsm_4_1_166.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T01:34:43Z","timestamp":1711416883000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/4\/1\/166\/6889669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,1]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2007,1,1]]},"published-print":{"date-parts":[[2007,1,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1743-6109.2006.00402.x","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2007,1]]},"published":{"date-parts":[[2007,1,1]]}}}